抗C5a抗体vilobelimab治疗重症机械通气COVID-19患者(PANAMO):多中心双盲随机安慰剂对照3期试验
PANAMO试验在9国46家医院纳入368例接受有创机械通气、PaO2/FiO2 60-200 mmHg的COVID-19患者,随机给予vilobelimab 800 mg静脉注射(最多6剂)或安慰剂。28天全因死亡率vilobelimab组32%、安慰剂组42%(HR 0·73,95%CI 0·50-1·06;p=0·094),预设的非分层分析中HR 0·67(95%CI 0·48-0·96;p=0·027)。
要点
- 在有创机械通气的重症COVID-19患者中,vilobelimab联合标准治疗使28天全因死亡率由42%降至32%。
- 主要分析HR 0·73(95%CI 0·50-1·06;p=0·094)未达统计学显著,非分层预设分析HR 0·67(95%CI 0·48-0·96;p=0·027)显著。
- 安全性分析中严重治疗中出现的不良事件两组相近(59% vs 63%)。
核心结论
- 在标准治疗基础上加用vilobelimab可改善有创机械通气COVID-19患者的生存,并显著降低死亡率。
- vilobelimab可考虑作为此类患者的附加治疗,C5a在其他致ARDS病毒感染中的作用需进一步研究。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照3期试验,在荷兰、德国、法国、比利时、俄罗斯、巴西、秘鲁、墨西哥、南非共46家医院开展。
- 纳入18岁及以上、接受有创机械通气且首次输注时插管不超过48 h、PaO2/FiO2 60-200 mm Hg、过去14天确诊SARS-CoV-2感染(任何变异株)的患者。
- 按1:1随机分配至标准治疗加vilobelimab 800 mg静脉注射(最多6剂,第1、2、4、8、15、22天)或标准治疗加匹配安慰剂,出院后不再继续治疗。
- 主要终点为全分析集(所有随机分配患者,排除误随机者)28天全因死亡率,采用Kaplan-Meier分析;安全性分析纳入至少接受一次输注的患者。
主要发现
- 2020年10月1日至2021年10月4日共纳入368例进入ITT分析(全分析集),vilobelimab组177例、安慰剂组191例。
- vilobelimab组1例因误随机且未治疗被排除出主要分析;364例(99%)至少接受一剂研究治疗(安全性分析集)。
- 28天内vilobelimab组177例中54例(31%)死亡,安慰剂组191例中77例(40%)死亡。
- 28天全因死亡率vilobelimab组32%(95%CI 25-39)、安慰剂组42%(95%CI 35-49),HR 0·73(95%CI 0·50-1·06;p=0·094)。
- 预设的非分层分析中vilobelimab显著降低28天全因死亡率(HR 0·67,95%CI 0·48-0·96;p=0·027)。
关键数值与推荐
- 最常见TEAE:急性肾损伤vilobelimab组35/175(20%)vs安慰剂组40/189(21%);肺炎38/175(22%)vs 26/189(14%);感染性休克24/175(14%)vs 31/189(16%)。
- 严重治疗中出现的不良事件:vilobelimab组103/175(59%)vs安慰剂组120/189(63%)。
临床怎么用
- 对于接受有创机械通气的重症COVID-19患者,可在标准治疗基础上考虑加用vilobelimab作为附加治疗。
- 用药方案为800 mg静脉注射,最多6剂(第1、2、4、8、15、22天),出院后不再继续。
- 主要终点未达统计学显著而预设非分层分析显著,临床决策需结合整体证据谨慎评估。
局限性
- 主要终点28天全因死亡率在分层分析中未达统计学显著(p=0·094),仅预设非分层分析显著。
- 研究仅针对COVID-19相关呼吸衰竭,结论不宜直接外推至其他病毒所致ARDS。
- 纳入时间窗要求插管不超过48 h且PaO2/FiO2 60-200 mm Hg,适用人群较窄。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vilobelimab, an anti-C5a monoclonal antibody, was shown to be safe in a phase 2 trial of invasively mechanically ventilated patients with COVID-19. Here, we aimed to determine whether vilobelimab in addition to standard of care improves survival outcomes in this patient population. METHODS: This randomised, double-blind, placebo-controlled, multicentre phase 3 trial was performed at 46 hospitals in the Netherlands, Germany, France, Belgium, Russia, Brazil, Peru, Mexico, and South Africa. Participants aged 18 years or older who were receiving invasive mechanical ventilation, but not more than 48 h after intubation at time of first infusion, had a PaO2/FiO2 ratio of 60-200 mm Hg, and a confirmed SARS-CoV-2 infection with any variant in the past 14 days were eligible for this study. Eligible patients were randomly assigned (1:1) to receive standard of care and vilobelimab at a dose of 800 mg intravenously for a maximum of six doses (days 1, 2, 4, 8, 15, and 22) or standard of care and a matching placebo using permuted block randomisation. Treatment was not continued after hospital discharge. Participants, caregivers, and assessors were masked to group assignment. The primary outcome was defined as all-cause mortality at 28 days in the full analysis set (defined as all randomly assigned participants regardless of whether a patient started treatment, excluding patients randomly assigned in error) and measured using Kaplan-Meier analysis. Safety analyses included all patients who had received at least one infusion of either vilobelimab or placebo. This study is registered with ClinicalTrials.gov, NCT04333420. FINDINGS: From Oct 1, 2020, to Oct 4, 2021, we included 368 patients in the ITT analysis (full analysis set; 177 in the vilobelimab group and 191 in the placebo group). One patient in the vilobelimab group was excluded from the primary analysis due to random assignment in error without treatment. At least one dose of study treatment was given to 364 (99%) patients (safety analysis set). 54 patients (31%) of 177 in the vilobelimab group and 77 patients (40%) of 191 in the placebo group died in the first 28 days. The all-cause mortality rate at 28 days was 32% (95% CI 25-39) in the vilobelimab group and 42% (35-49) in the placebo group (hazard ratio 0·73, 95% CI 0·50-1·06; p=0·094). In the predefined analysis without site-stratification, vilobelimab significantly reduced all-cause mortality at 28 days (HR 0·67, 95% CI 0·48-0·96; p=0·027). The most common TEAEs were acute kidney injury (35 [20%] of 175 in the vilobelimab group vs 40 [21%] of 189 in the placebo), pneumonia (38 [22%] vs 26 [14%]), and septic shock (24 [14%] vs 31 [16%]). Serious treatment-emergent adverse events were reported in 103 (59%) of 175 patients in the vilobelimab group versus 120 (63%) of 189 in the placebo group. INTERPRETATION: In addition to standard of care, vilobelimab improves survival of invasive mechanically ventilated patients with COVID-19 and leads to a significant decrease in mortality. Vilobelimab could be considered as an additional therapy for patients in this setting and further research is needed on the role of vilobelimab and C5a in other acute respiratory distress syndrome-causing viral infections. FUNDING: InflaRx and the German Federal Government.
引用
- Vlaar APJ, Witzenrath M, van Paassen P, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022. PMID: 36087611. doi:10.1016/S2213-2600(22)00297-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。